This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
by Kinjel Shah
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
Is Invesco Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw AbbVie (ABBV) settling at $191.50, representing a +1.06% change from its previous close.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
by Sundeep Ganoria
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
by Sundeep Ganoria
Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
The latest trading day saw AbbVie (ABBV) settling at $187.66, representing a +0.17% change from its previous close.
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
by Urmimala Biswas
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw AbbVie (ABBV) settling at $186.11, representing a +0.26% change from its previous close.
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands
by Zacks Equity Research
Zacks highlights strong showings from ABBV, ISRG, HBB and AXIL, while BRK.B gains on insurance growth and capital strength despite headwinds.
Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical
by Mark Vickery
Berkshire Hathaway, AbbVie and Intuitive Surgical beat estimates as analysts highlight growth drivers, headwinds and strategic moves in new reports.
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?
by Kinjel Shah
ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
by Zacks Equity Research
Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie
by Zacks Equity Research
Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.
Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals
by Kinjel Shah
Bayer reports first-quarter results. NVO and GSK announce licensing deals with smaller biotechs.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
by Zacks Equity Research
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
by Kinjel Shah
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL